Company intelligence / Profile preview

Lamellar Biomedical

Bellshill/Glasgow, Scotland, United Kingdomx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Lamellar Biomedical developed a proprietary nanotechnology-based drug delivery platform called Lamellasome™, designed to alter mucus properties, disperse biofilms, and fight infection. Their lead programs targeted severe respiratory conditions such as cystic fibrosis and idiopathic pulmonary fibrosis. The company advanced at least one program into clinical trials but was dissolved in May 2024.

Therapeutic areas: PulmonologyOther
Modalities: Gene therapymiRNA-based therapyNanoparticleSmall moleculeMedical device
Industry: Biotech

Drug pipeline

3 assets

Lamellasome IPF-NA

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Not explicitly listed; no major pharma partnerships identified in available sources.

Beyond the preview

Go deeper on Lamellar Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lamellar Biomedical.

Explore the full profile